Last updated: 2026-09-08 15:38:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
MiNK Therapeutics, Inc. (INKT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $11.66, with a market capitalization of $59.40M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.48 to $16.98. This page covers its latest market performance, valuation, price trends and company information.
$59.40M | |
$11.61 | |
$221.55 | |
$4.56 | |
-- | |
7.03K | |
14.41K | |
-- | |
$16.98 | |
$8.48 | |
-- | |
-- |
MiNK Therapeutics, Inc. (INKT) is currently trading at $11.66 as of 2026-09-08 15:35:00, -- from the previous close of $0.00
During today's regular trading session, INKT has traded between $4.56 and $221.55, with a trading volume of 7.03K shares. The current price is near the lower end of today's range.
Over the past seven days, MiNK Therapeutics, Inc. (INKT) moved from $11.68 to $11.66, representing a decline of 0.21% ($0.02).
The stock traded between $10.82 and $11.80 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 6.16 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 37.4%
INKT is currently trading at $11.66, placing it 37.4% of the way from its 52-week low of $8.48 to its 52-week high of $16.98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 15 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MiNK Therapeutics, Inc. (INKT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.